Literature DB >> 28295039

Deciphering the mechanism of Q145H SFTPC mutation unmasks a splicing defect and explains the severity of the phenotype.

Céline Delestrain1,2,3,4, Stéphanie Simon1,3,4, Abdel Aissat1,3,4,5, Rachel Medina1,5, Xavier Decrouy3,6, Elodie Nattes1,2,4, Agathe Tarze1,3,4, Bruno Costes1,2, Pascale Fanen1,3,4,5, Ralph Epaud1,2,3,4.   

Abstract

Mutations in the gene encoding surfactant protein C (SFTPC) have led to a broad range of phenotypes from neonatal respiratory distress syndrome to adult interstitial lung disease. We previously identified the c.435G>C variant in the SFTPC gene associated with fatal neonatal respiratory distress syndrome in an infant girl. Although this variation is predicted to change glutamine (Q) at position 145 to histidine (H), its position at the last base of exon 4 and the severity of the phenotype suggested that it might also induce a splicing defect. To test this hypothesis, we used hybrid minigene, biochemical and immunofluorescence tools to decipher the molecular mechanism of the mutation. Immunoblotting and confocal imaging showed similar maturation and localization of wild-type and Q145H proteins, but hybrid minigene analysis showed complete exon 4 skipping. Since the exon 4 is in frame, a putative truncated protein of 160 amino acids would be produced. We have shown that this truncated protein had an altered intracellular trafficking and maturation. The c.435G>C mutation is deleterious not because of its amino acid substitution but because of its subsequent splicing defect and should be referred to as r.325_435del and p.Leu109_Gln145del. The absence of residual full-length transcripts fully explained the severity of the phenotype we observed in the infant.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28295039      PMCID: PMC5477364          DOI: 10.1038/ejhg.2017.36

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  13 in total

1.  A mutation in the surfactant protein C gene associated with familial interstitial lung disease.

Authors:  L M Nogee; A E Dunbar; S E Wert; F Askin; A Hamvas; J A Whitsett
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

2.  A nonaggregating surfactant protein C mutant is misdirected to early endosomes and disrupts phospholipid recycling.

Authors:  Michael F Beers; Arie Hawkins; Jean Ann Maguire; Adam Kotorashvili; Ming Zhao; Jennifer L Newitt; Wenge Ding; Scott Russo; Susan Guttentag; Linda Gonzales; Surafel Mulugeta
Journal:  Traffic       Date:  2011-06-28       Impact factor: 6.215

3.  Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative.

Authors:  Wen-Jing Wang; Surafel Mulugeta; Scott J Russo; Michael F Beers
Journal:  J Cell Sci       Date:  2003-02-15       Impact factor: 5.285

4.  Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level.

Authors:  Abdel Aissat; Alix de Becdelièvre; Lisa Golmard; Christian Vasseur; Catherine Costa; Asma Chaoui; Natacha Martin; Bruno Costes; Michel Goossens; Emmanuelle Girodon; Pascale Fanen; Alexandre Hinzpeter
Journal:  Hum Mutat       Date:  2013-03-28       Impact factor: 4.878

5.  New surfactant protein C gene mutations associated with diffuse lung disease.

Authors:  L Guillot; R Epaud; G Thouvenin; L Jonard; A Mohsni; R Couderc; F Counil; J de Blic; R A Taam; M Le Bourgeois; P Reix; F Flamein; A Clement; D Feldmann
Journal:  J Med Genet       Date:  2009-05-13       Impact factor: 6.318

Review 6.  RNA mis-splicing in disease.

Authors:  Marina M Scotti; Maurice S Swanson
Journal:  Nat Rev Genet       Date:  2015-11-23       Impact factor: 53.242

7.  SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress.

Authors:  Tobias Thurm; Eva Kaltenborn; Sunčana Kern; Matthias Griese; Ralf Zarbock
Journal:  Eur J Clin Invest       Date:  2013-05-24       Impact factor: 4.686

Review 8.  A novel surfactant protein C gene mutation associated with progressive respiratory failure in infancy.

Authors:  Melissa Kaori Silva Litao; Don Hayes; Saurabh Chiwane; Lawrence M Nogee; Geoffrey Kurland; Lokesh Guglani
Journal:  Pediatr Pulmonol       Date:  2016-06-30

9.  Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I.

Authors:  R Pérez-Carro; R Sánchez-Alcudia; B Pérez; R Navarrete; C Pérez-Cerdá; M Ugarte; L R Desviat
Journal:  Clin Genet       Date:  2013-08-21       Impact factor: 4.438

10.  Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier.

Authors:  Alexandre Hinzpeter; Abdel Aissat; Elvira Sondo; Catherine Costa; Nicole Arous; Christine Gameiro; Natacha Martin; Agathe Tarze; Laurence Weiss; Alix de Becdelièvre; Bruno Costes; Michel Goossens; Luis J Galietta; Emmanuelle Girodon; Pascale Fanen
Journal:  PLoS Genet       Date:  2010-10-07       Impact factor: 5.917

View more
  2 in total

1.  Child Interstitial Lung Disease in an Infant with Surfactant Protein C Dysfunction due to c.202G>T Variant (p.V68F).

Authors:  Hyunbin Park; Aneela Bidiwala; Laura A Conrad; Nasr Aborawi; Michelle Ewart; Maureen Josephson; Lawrence M Nogee; Raanan Arens
Journal:  Lung       Date:  2022-01-16       Impact factor: 2.584

2.  Biologic characterization of ABCA3 variants in lung tissue from infants and children with ABCA3 deficiency.

Authors:  Kathryn K Xu; Daniel J Wegner; Lucille C Geurts; Hillary B Heins; Ping Yang; Aaron Hamvas; Pirooz Eghtesady; Stuart C Sweet; F Sessions Cole; Jennifer A Wambach
Journal:  Pediatr Pulmonol       Date:  2022-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.